Article Text

Download PDFPDF
Association between statin use and the risks of glaucoma in Australia: a 10-year cohort study
  1. Yixiong Yuan1,
  2. Wei Wang1,
  3. Xianwen Shang2,
  4. Ruilin Xiong1,
  5. Jason Ha3,
  6. Lei Zhang3,4,5,6,
  7. Zhuoting Zhu2,
  8. Mingguang He1,2,3,7
  1. 1State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China
  2. 2Guangdong Eye Institute, Department of Ophthalmology, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China
  3. 3Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia
  4. 4Artificial Intelligence and Modelling in Epidemiology Program, Melbourne Sexual Health Centre, Alfred Health, Melbourne, Victoria, Australia
  5. 5Central Clinical School, Faculty of Medicine, Monash University, Melbourne, Victoria, Australia
  6. 6Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou, Henan, China
  7. 7Ophthalmology, Department of Surgery, University of Melbourne, Melbourne, Victoria, Australia
  1. Correspondence to Professor Mingguang He, Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Australia; mingguang.he{at}unimelb.edu.au; Dr Zhuoting Zhu, Guangdong Eye Institute, Department of Ophthalmology, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China; zhuoting_zhu{at}hotmail.com

Abstract

Synopsis In a cohort of middle-aged and elderly Australians, we found that long-term statin use was associated with a higher risk of glaucoma onset. As to subtypes of statins, the increased risk was only found in rosuvastatin users.

Purpose To investigate the relationship between statin use and glaucoma onset in a 10-year longitudinal study.

Methods This nested case–control study was based on data from a large-scale cohort of Australians aged over 45 years old. Medication exposure was identified by claims records from the Pharmaceutical Benefits Scheme during the follow-up period (2009–2016). The onset of glaucoma was defined as the people with at least three claims of antiglaucoma medications. Controls matched by age, gender and cardiovascular diseases were selected from participants without prescription of antiglaucoma medications. A conditional logistic regression model was used to assess the association between statin use and glaucoma onset.

Results The proportion of statin users was higher in the case group (40.5%) than that in the control group (38.4%). After adjusting for baseline characteristics and longitudinal claims records, statin use was not associated with glaucoma onset (OR 1.04, 95% CI 0.97 to 1.11). However, an increased risk of glaucoma onset was observed in participants with a longer duration of statin use (>3 years vs <1 year: OR 1.12, 95% CI 1.04 to 1.21). With respect to specific types of statins, participants taking rosuvastatin were more likely to suffer from glaucoma (OR 1.11, 95%CI 1.01 to 1.22). The use of other statins was not significantly associated with glaucoma onset.

Conclusions Long-term statin use was found to be associated with a higher risk of glaucoma onset in this study. Regarding specific types of statins, the increased risk of glaucoma onset was only observed in users of rosuvastatin.

  • Glaucoma
  • Epidemiology
  • Drugs

Data availability statement

Data are available in a public, open access repository. The 45 and Up Study is conducted by the Sax Institute in collaboration with major partners (www.saxinstitute.org.au). Claims records in the MBS and PBS database were supplied by Services Australia (formerly Department of Human Services; https://www.servicesaustralia.gov.au). All data retrieval and linkage need formal applications to the Sax Institute and Services Australia.

Statistics from Altmetric.com

Data availability statement

Data are available in a public, open access repository. The 45 and Up Study is conducted by the Sax Institute in collaboration with major partners (www.saxinstitute.org.au). Claims records in the MBS and PBS database were supplied by Services Australia (formerly Department of Human Services; https://www.servicesaustralia.gov.au). All data retrieval and linkage need formal applications to the Sax Institute and Services Australia.

View Full Text

Footnotes

  • Contributors Study design: YY, WW and RX; Statistical analysis: XS; Critical supervision: LZ and JH; Article writing: YY; Conception and manuscript overseeing: ZZ and MH.

  • Funding MH receives support from the University of Melbourne Research Accelerator Program and the Centre for Eye Research Australia Foundation. The Centre for Eye Research Australia receives Operational Infrastructure Support from the Victorian State Government. MH is supported by NHMRC Investigator Grant (APP1175405) and by the Fundamental Research Funds of the State Key Laboratory in Ophthalmology (No grant numbers).

  • Disclaimer The sponsor or funding organisation had no role in the design or conduct of this research.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.